Recordati stock
Price history
+1.15% over the period1 year: from €52.25 (November 17, 2025) to €52.85 (November 16, 2026), +1.15%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | €52.85 |
| October 30, 2026 | €53.00 |
| September 30, 2026 | €52.65 |
| August 31, 2026 | €52.55 |
| July 31, 2026 | €51.65 |
| June 30, 2026 | €51.30 |
| May 29, 2026 | €51.50 |
| April 30, 2026 | €49.64 |
| March 31, 2026 | €49.04 |
| February 27, 2026 | €48.42 |
| January 30, 2026 | €46.34 |
| December 30, 2025 | €48.54 |
| November 28, 2025 | €50.90 |
| November 17, 2025 | €52.25 |
At a glance
The company
Researches, develops, produces and sells pharmaceutical products for specialty care, primary care and rare diseases across multiple markets
Latest results
Quarter to September 30, 2026 · EPS €0.66 (estimate €0.79)
TickerLandia's take on Recordati
- Priced as usual relative to earnings: P/E on the latest fiscal year 25 vs a median of 26 over its last 10 fiscal years.
- Priced in line with similar companies: trailing 12-month P/E 21 vs 21 (−2%) in a group of 10.
- Strong point: Earnings stability (74/100 in its group). Weak point: Financial strength (30/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−1.77% from the 52-week high
Analysts · 7 analysts
Average target€56.35+6.62% vs. price
Buy 1 · Hold 5 · Sell 1 · Hold
TickerLandia Fingerprint: Recordati
Compared with similar companies: very low risk.
Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Priceaverage47
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 21.0 41 Forward P/E 13.9 35 Price/book 4.65 48 Price/sales 3.96 58 EV/EBITDA 11.6 50 Profitabilityhigh60
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 73.8% 54 Operating margin 32.6% 58 ROA 10.5% 54 Net margin 19.0% 70 ROE 24.6% 65 Earnings stabilityhigh74
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1.0% 94 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 54 Growthhigh70
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +12.21% 82 Revenue growth (year over year) +9.60% 58 Earnings growth (year over year) +24.90% 69 Financial strengthlow30
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 2.07 22 Interest coverage 7.93 22 Current ratio 1.34 38 Debt/equitycounts in reverse: lower means more financial strength 0.94 40 Dividendaverage56
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 32 years 68 Payout ratio 53.4% 40 Dividend yield 2.7% 60 Market momentumaverage50
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +1.06% 35 Relative strength (3 months) +3.24% 62 Relative strength (6 months) −3.02% 51 Distance from 200-day average +3.73% 51 Riskvery low8
How much the price swings.
Metric Value Position in group Beta (1 year) 0.15 6 Volatility (60 days) 7.7% 2 Maximum drawdown (12 months) 15.8% 17
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Recordati is priced as in the past and in line with similar companies
On the latest fiscal year's earnings (2025), Recordati's P/E today is 24.9, in line with the median of its last 10 fiscal years (25.7; between 20.3 and 30.6 from 2016 to 2025). Recordati's P/E (trailing 12 months): 21.0, in line with the median of a group of 10 similar companies (21.5).
Compared with 10 similar companies
| Metric | Recordati | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 21.0 | Middle | |
| Forward P/E | 13.9 | Middle | |
| Operating margin | 32.6% | Middle | |
| ROE | 24.6% | Middle | |
| Debt/equity | 0.94 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Recordati. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€692.92M
Latest quarter · Q3 2026
Net income
€137.43M
Latest quarter · Q3 2026
Quarterly net margin
19.8%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- €10.96B
- P/E
- 21.0
- EPS
- €2.51
- Volume
- 516.94K
- Daily trading
- €31.12M
- Dividend yield
- 2.54%
- Last ex-dividend on May 18, 2026
How Recordati is changing
All resultsRevenue grew 12.6% a year on average over the last 5 years
Profits turn into cash: free cash flow equal to 124% of net income
Revenue has grown for 5 fiscal years in a row
Returns
Recordati returns with dividends
€1,000 invested in Recordati 5 years ago, on November 16, 2021, would be worth €1,058 today with dividends reinvested: +5.79% in total, +1.13% per year. On price alone it would be €932 (−6.79%).
| Period | Recordati | FTSE MIB | €1,000 becomes |
|---|---|---|---|
| 1 month | −0.19% | +3.60% | €998 |
| 6 months | +2.62% | +5.58% | €1,026 |
| Year to date | +8.88% | +15.38% | €1,089 |
| 1 year | +3.85% | +18.49% | €1,039 |
| 3 years | +28.07% | +77.25% | €1,281 |
| 5 years | +5.79% | +86.51% | €1,058 |
| 10 years | +167.10% | +213.16% | €2,671 |
Over the last 6 months it has done better than 20% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. FTSE MIB: price only. Calculate your investment
The chart in detail
Recordati: technical analysis
Recordati is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 13.3% below its all-time closing high (€60.95, February 13, 2025).
- Trend
- Upward
- RSI (14 sessions)
- 49
- Between 30 and 70
- vs 200-session average
- +4.08%
Support and resistance
Price areas where Recordati has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance€53.35+0.95%7 touches, last on November 6, 2026
- Last price€52.85
- Support€52.60−0.47%7 touches, last on October 28, 2026
- Support€51.39−2.76%13 touches, last on September 7, 2026
- Support€50.49−4.46%6 touches, last on June 18, 2026
Volatility and risk
Over the last year it has moved little with the FTSE MIB.
- Beta (1 year) vs FTSE MIB
- 0.16
- Volatility (60 sessions, annualised)
- 7.7%
- Largest fall in the last year
- −14.87%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Recordati: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Recordati has been January: +3.27% on average, positive in 22 years out of 36. The weakest has been September: −1.77% on average, positive in 15 years out of 37. November, the current month, has been positive in 19 years out of 36 (+2.20% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +3.27% | +3.00% | 22 of 36 |
| February | +3.06% | +1.43% | 24 of 37 |
| March | +1.67% | +1.05% | 20 of 37 |
| April | +2.54% | +1.22% | 23 of 37 |
| May | +2.60% | +1.83% | 25 of 37 |
| June | −0.12% | −0.53% | 16 of 37 |
| July | +1.28% | +0.68% | 22 of 37 |
| August | −0.69% | −0.64% | 16 of 37 |
| September | −1.77% | −1.99% | 15 of 37 |
| October | +1.85% | +2.33% | 23 of 37 |
| November | +2.20% | +0.69% | 19 of 36 |
| December | −0.69% | −0.66% | 17 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Recordati and its competitors
With revenue of EUR 2.6 billion in the fiscal year ended 31 December 2025, the group researches, develops, produces and sells pharmaceuticals through two business areas, Specialty and Primary Care and Rare Diseases. Its portfolio includes treatments for rare conditions such as maple syrup urine disease, Cushing's syndrome and cystinosis, with Carbaglu, Cystadrops and Isturisa, alongside cardiovascular and urology products such as Zanidip and Urorec, and oncology products including Eligard and Fotivda.
- Headquarters
- Milan, Italy
- Employees
- 4,700
- Founded
- 1926
- Chief executive
- Robert Koremans
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| RecordatiREC | $12.11B | 32.6% | 21.0 | +2.62% |
| OrionORNAV | $15.93B | 38.1% | 22.0 | +52.14% |
| GrifolsGRF | $8.76B | 18.9% | 16.4 | +28.19% |
| VirbacVIRP | $3.28B | 15.8% | 19.1 | +2.00% |
| BayerBAYN | $61.37B | 16.5% | — | +51.26% |
| GSKGSK | $101.36B | 30.5% | 17.9 | +3.57% |
Same industry or related industries, similar size. Compare Recordati with its competitors · Full profile
